Aeglea Bio Therapeutics Inc (AGLE) Financials

$27.60

$-0.06 (-0.22%)

As on 30-Jan-2024 09:30EDT

Market cap

$49 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

0.4

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	1.05	2.33	18.74	0.02	--	3.89
Cost of Revenue	--	--	--	--	64.60	36.72
Gross Profit	1.05	2.33	18.74	0.02	-64.60	3.89
Operating Expenses	101.03	87.11	84.39	81.48	80.33	49.35
Operating Profit (EBIT)	-215.55	-84.78	-65.65	-81.48	-80.33	-45.46
Other Income	-57.83	--	-0.01	0.59	2.08	1.12
Profit before Tax	-294.42	-83.95	-65.66	-80.89	-78.25	-44.35
Provision for Tax	0.01	-0.14	0.14	-0.59	-2.56	-0.06
Profit after Tax (Net Income)	-294.43	-83.82	-65.80	-80.30	-75.69	-44.35
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-452.98	-83.82	-65.80	-80.89	-78.25	-44.35

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	-245.40	50.31	83.94	139.83	60.08	67.43
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	407.80	6.18	5.84	5.34	4.74	0.07
Current Liabilities	44.87	14.66	20.14	16.44	18.36	10.24
Total Liabilities	252.14	71.14	109.93	161.62	83.18	77.74

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	1.32	8.89	11.04	11.83	8.68	1.07
Current Assets	205.95	62.26	98.89	149.79	74.51	76.67
Total Assets	252.14	71.14	109.93	161.62	83.18	77.74
Total Debt*	--	4.63	5.04	5.45	5.06	--
Net Current Assets	161.08	47.60	78.75	133.35	56.15	66.43

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-80.14	-53.72	-75.78	-65.69	-32.19
Cash Flow from Investing Activities	--	57.01	-22.62	-7.60	-1.74	-15.23
Cash from Financing Activities	--	42.68	1.39	154.51	65.72	57.07
Net Cash Inflow / Outflow	--	--	-74.94	71.13	-1.71	9.64

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	--	-72.99	-8.79	-9.98	-12.34	-22.93
Cash EPS ($)	--	--	-8.62	-9.74	-12.19	-22.80
Adjusted Book Value ($)	--	--	5.27	12.73	21.49	18.20
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	-8.40	-8.14	-11.65	-19.90
Free Cash Flow per Share ($)	--	--	-8.40	-8.23	-12.30	-20.35

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	--	-116.48	-56.18	-76.32	-114.19
ROE (%)	--	--	-124.87	-58.81	-80.33	-118.73
ROA (%)	--	-162.95	-92.58	-48.46	-65.60	-94.07
EBIT Margin (%)	--	11,531.69	-3,640.23	-350.33	-373,030.26	--
Net Margin (%)	--	518.60	-3,598.75	-351.35	-13,167.32	-3,639.09
Cash Profit Margin (%)	--	-0.02	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	--	-81.84	-0.88	856.89	--	-1.00
EBIT Growth (%)	--	241.23	-29.14	19.43	-1.43	-81.14
Net Profit Growth (%)	--	-397.34	-27.38	18.06	-6.09	-70.68
EPS Growth (%)	--	-204.31	0.12	0.19	0.46	-0.24
Book Value Growth (%)	--	-418.77	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	--	-0.05	-0.48	-0.64	-0.33
Price / Book Value	--	0.35	0.09	0.37	0.37	0.42
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	--	-3.88	0.56	0.89	1.11	0.52
Close Price ($)	--	12.25	11.25	118.75	196.75	191.00
High Price ($)	--	39.00	120.75	219.75	284.50	236.25
Low Price ($)	--	2.66	8.50	86.75	87.50	149.75
Market Cap ($ Cr)	--	48.63	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	--	--	0.09	0.06	0.04	0.08
Short term debt to equity ratio	--	--	0.01	0.01	0.00	0.01
Current Ratio	--	4.59	4.25	4.91	9.11	4.06
Quick Ratio	--	4.59	--	4.95	--	--
Interest Coverage	--	-353.72	-101.29	-41.95	-137.40	--

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	--	15.46	16.10	4.35	--	--
Asset Turnover	--	0.01	0.03	0.14	0.00	--
Receivable days	--	--	93.31	15.89	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	10.79
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.